Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 14, 2010, Pages 6471-6476

  Liu, Meng ^a,b   Sjogren, Anna Karin M ^a   Karlsson, Christin ^a   Ibrahim, Mohamed X ^a   Andersson, Karin M E ^a   Olofsson, Frida J ^a   Wahlstrom, Annika M ^a   Dalin, Martin ^a   Yu, Huiming ^b   Chen, Zhenggang ^a,b   Yang, Shao H ^c   Young, Stephen G ^c   Bergo, Martin O ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mouse models; Non small cell lung cancer; Protein farnesyltransferase; Protein geranylgeranyltransferase type

Indexed keywords

GERANYLGERANYLTRANSFERASE 1; GERANYLTRANSFERASE; H RAS PROTEIN; HDJ2 PROTEIN; K RAS PROTEIN; PROTEIN; PROTEIN FARNESYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL MEMBRANE; CELL PROLIFERATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; ENZYME DEFICIENCY; ENZYME INACTIVATION; FARNESYLATION; FIBROBLAST; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING;

ALKYL AND ARYL TRANSFERASES; ALLELES; ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DIMETHYLALLYLTRANSTRANSFERASE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS);

MUS;

EID: 77950904083     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0908396107     Document Type: Article

References (41)

1. Lane KT, Beese LS (2006) Lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res 47:681-699.
2. Seabra MC, Reiss Y, Casey PJ, Brown MS, Goldstein JL (1991) Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. Cell 65:429-434. (Pubitemid 121002052)
3. Casey PJ, Seabra MC (1996) Protein prenyltransferases. J Biol Chem 271:5289-5292.
4. Kato K, et al. (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89:6403-6407.
5. Bos JL (1989) ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689. (Pubitemid 19213607)
6. Basso AD, Kirschmeier P, Bishop WR (2006) Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47:15-31.
7. Kohl NE, et al. (1995) Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1:792-797.
8. Omer CA, et al. (2000) Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res 60:2680-2688.
9. Sepp-Lorenzino L, et al. (1995) A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55:5302-5309.
10. Sebti SM, Hamilton AD (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies. Oncogene 19:6584-6593.
11. Sebti SM, Der CJ (2003) Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 3:945-951.
12. End DW, et al. (2001) Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131-137. (Pubitemid 32095710)
13. Liu M, et al. (1998) Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wapras transgenic mice. Cancer Res 58:4947-4956. (Pubitemid 28503695)
14. Rose WC, et al. (2001) Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res 61:7507-7517.
15. Hunt JT, et al. (2000) Discovery of (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H- imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1, 4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem43:3587-3595.
16. Mijimolle N, et al. (2005) Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell 7:313-324. (Pubitemid 40544649)
17. Lerner EC, et al. (1995) Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270:26802-26806.
18. Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, Lowy DR (1984) The p21 ras C-terminus is required for transformation and membrane association. Nature 310:583-586. (Pubitemid 14053901)
19. Ashar HR, et al. (2000) Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275:30451-30457.
20. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM (2001) The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 276:16161-16167. (Pubitemid 37391656)
21. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM (1995) Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55:5310-5314.
22. Yang SH, et al. (2009) Caution! Analyze transcripts from conditional knockout alleles. Transgenic Res 18:483-489.
23. V12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc Natl Acad Sci USA 93:4454-4458.
24. Whyte DB, et al. (1997) K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459-14464. (Pubitemid 27232866)
25. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM (1997) Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 272:14093-14097.
26. El Oualid F, Cohen LH, van der Marel GA, Overhand M (2006) Inhibitors of protein: Geranylgeranyl transferases. Curr Med Chem 13:2385-2427.
27. Sun J, Qian Y, Hamilton AD, Sebti SM (1998) Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467-1473. (Pubitemid 28151853)
28. Sun J, et al. (1999) Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase andgeranylgeranyltransferase I:Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 59:4919-4926. (Pubitemid 29472897)
29. Sun J, et al. (2003) Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Res 63:8922-8929. (Pubitemid 38064072)
30. Peterson YK, Kelly P, Weinbaum CA, Casey PJ (2006) A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J Biol Chem 281:12445-12450. (Pubitemid 43855330)
31. Watanabe M, et al. (2008) Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 283:9571-9579.
32. Sjogren A-KM, et al. (2007) GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest 117:1294-1304.
33. Lobell RB, et al. (2001) Evaluation of farnesyl:protein transferase and geranylgeranyl: protein transferase inhibitor combinations in preclinical models. Cancer Res 61:8758-8768.
34. deSolms SJ, et al. (2003) Dual protein farnesyltransferase- geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents. J Med Chem 46:2973-2984.
35. Di Paolo A, et al. (2001) Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells. Br J Cancer 84:1535-1543. (Pubitemid 32579347)
36. Lakso M, et al. (1996) Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci USA 93:5860-5865. (Pubitemid 26190768)
37. Schwenk F, Baron U, Rajewsky K (1995) A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 23:5080-5081. (Pubitemid 26012492)
38. Jackson EL, et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15:3243-3248.
39. Adjei AA, et al. (2000) A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity. Cancer Res 60:1871-1877.
40. Lebowitz PF, Prendergast GC (1998) Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho. Oncogene 17 (11 Reviews):1439-1445.
41. Hanks M, Wurst W, Anson-Cartwright L, Auerbach AB, Joyner AL (1995) Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2. Science 269:679-682.